This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Protocol for augmenting β cell regeneration and reversing late-stage type 1 diabetes	<p>A protocol using an antibody and a cell transplant conditioning regimen plus delivery of gastrin and epidermal growth factor (EGF) could help treat late-stage type 1 diabetes. The protocol involves delivering anti-CD3 and anti-CD8A (p32; CD8) antibodies followed by transplantation with donor bone marrow and CD4⁺-depleted spleen cells, followed by daily injections of gastrin and EGF for up to 60 days. In a mouse model of late-stage type 1 diabetes, the protocol restored normal glycemia in 7 of 12 animals for up to 150 days, whereas conditioning regimen or gastrin plus EGF alone did not restore normal glycemia in any animals. Next steps include optimizing the growth factor regimen and evaluating the combination approach in large animal models.</p> <p>SciBX 5(21); doi:10.1038/scibx.2012.563 Published online May 24, 2012</p>	<p>Conditioning regimen covered by issued and pending patents; available for licensing from City of Hope</p> <p>Contact: Matthew Gruneth, City of Hope, Duarte, Calif. e-mail: mgruneth@coh.org</p>	<p>Wang, M. <i>et al. Sci. Transl. Med.</i>; published online May 9, 2012; doi:10.1126/scitranslmed.3003835</p> <p>Contact: Defu Zeng, Beckman Research Institute at City of Hope, Duarte, Calif. e-mail: dzeng@coh.org</p>